- UK government scoops the US in authorizing the use of the Pfizer/BioNTech vaccine; roll out to commence next week. FDA and EU approval probably not far off.
- The Pfizer/BioNTech vaccine has first mover advantage. BioNTech stock could experience further gains at least in the short term. Moderna is likely to get a boost too.
- Treatments seem to be going backwards with doubts about remdesivir and lacklustre monoclonal antibody treatments for early stage disease from Regeneron and Eli Lilly.
- With Europe and the US confronting new outbreaks, expect a tough winter and the need for restrictions and lockdowns, which might mean market setback unless substantial additional government support is given.
For further details see:
COVID-19 Update: Vaccines, Treatments And Lockdowns, Investment Implications